News & Events about Allakos Inc.
Allakos Inc. (NASDAQ:ALLK Get Rating) Equities researchers at Jefferies Financial Group lifted their FY2022 EPS estimates for Allakos in a note issued to investors on Monday, November 7th. Jefferies Financial Group analyst M. Raycroft now expects that the company will post earnings per share of ($5....
Globe Newswire
2 months ago
Siglec-10 is a myeloid checkpoint receptor selectively expressed on tumor associated macrophages and dendritic cells AK007 potently blocks all known ligand interaction with Siglec-10, including the dont eat me signal CD24 Monotherapy treatment with a Siglec-10 antagonist antibody polarized tumor-...
Thinking about buying stock in Purple Innovation, Knowbe4, Allakos, Larimar Therapeutics, or Alzamend Neuro? Thinking about buying stock in Purple Innovation, Knowbe4, Allakos, Larimar Therapeutics, or Alzamend Neuro? PR Newswire NEW YORK, Sept. 19, 2022 NEW YORK, Sept. 19, 2022 /PRNewswire...
Globe Newswire
4 months ago
Lirentelimab met histologic co-primary endpoint but missed symptomatic co-primary endpoint SAN CARLOS, Calif., Sept. 09, 2022 (GLOBE NEWSWIRE) -- Allakos Inc. (the Company) (Nasdaq: ALLK), a biotechnology company developing lirentelimab (AK002) and AK006 for the treatment of allergic and ...
Ticker Report
4 months ago
Healthcare of Ontario Pension Plan Trust Fund acquired a new stake in Allakos Inc. (NASDAQ:ALLK Get Rating) in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm acquired 233,600 shares of the companys stock, ...